secwatch.observer — SEC 8-K summary
======================================

Issuer:     PAVmed Inc. (PAVM)
CIK:        0001624326
Form:       8-K
Filed at:   2023-11-15T23:59:59+00:00
Accession:  0001493152-23-041370
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PAVmed Q3 revenue $0.8M, net loss $0.16/share; Lucid revenue surges 392% sequentially
--------------------------------------------------------------------------------

- Q3 2023 revenue $0.8M; GAAP net loss $17.7M ($0.16 per share), non-GAAP adjusted loss $9.7M ($0.09).
- Lucid generated $783K revenue, up 392% sequentially; EsoGuard testing volumes up 17% sequentially and 137% YoY.
- Cash and equivalents $26.4M at Sept 30, down from $37.2M at June 30, reflecting ongoing cash burn.
- Veris Health launching next-gen Cancer Care Platform in Q4; on track for FDA 510(k) submission next year and implantable monitor in 2024.
- Lucid launched EsoGuard 2.0 with enhanced performance and lower per-sample costs; clinical utility data showed 98-100% concordance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1624326/000149315223041370/0001493152-23-041370-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1624326/000149315223041370/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-041370

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer